Encompass More Asset Management Purchases New Position in Tempus AI, Inc. $TEM

Encompass More Asset Management acquired a new position in Tempus AI, Inc. (NASDAQ:TEM) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,261 shares of the company’s stock, valued at approximately $990,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. grew its position in Tempus AI by 0.7% in the second quarter. China Universal Asset Management Co. Ltd. now owns 33,757 shares of the company’s stock worth $2,145,000 after acquiring an additional 226 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in shares of Tempus AI by 6.1% in the 2nd quarter. PNC Financial Services Group Inc. now owns 5,003 shares of the company’s stock valued at $318,000 after purchasing an additional 287 shares during the last quarter. Cranbrook Wealth Management LLC bought a new stake in Tempus AI in the third quarter worth $25,000. Concord Wealth Partners increased its position in Tempus AI by 308.0% during the second quarter. Concord Wealth Partners now owns 408 shares of the company’s stock worth $26,000 after buying an additional 308 shares during the last quarter. Finally, Sigma Planning Corp raised its holdings in Tempus AI by 1.0% during the second quarter. Sigma Planning Corp now owns 33,834 shares of the company’s stock valued at $2,150,000 after buying an additional 319 shares in the last quarter. Institutional investors own 24.22% of the company’s stock.

Tempus AI Stock Performance

Shares of NASDAQ TEM opened at $62.70 on Monday. Tempus AI, Inc. has a 12 month low of $31.36 and a 12 month high of $104.32. The company has a market cap of $11.15 billion, a P/E ratio of -52.69 and a beta of 5.00. The business’s 50 day moving average is $75.16 and its two-hundred day moving average is $73.76. The company has a quick ratio of 3.12, a current ratio of 3.28 and a debt-to-equity ratio of 2.45.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.05. Tempus AI had a negative return on equity of 73.21% and a negative net margin of 18.45%.The company had revenue of $334.21 million during the quarter, compared to analysts’ expectations of $328.89 million. During the same period in the prior year, the business earned ($0.46) earnings per share. Tempus AI’s revenue for the quarter was up 84.7% compared to the same quarter last year. On average, equities analysts expect that Tempus AI, Inc. will post -6.15 EPS for the current year.

Insider Transactions at Tempus AI

In related news, EVP Erik Phelps sold 1,302 shares of the stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $67.42, for a total value of $87,780.84. Following the completion of the sale, the executive vice president owned 89,280 shares in the company, valued at approximately $6,019,257.60. This trade represents a 1.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Ryan Fukushima sold 5,000 shares of Tempus AI stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $75.72, for a total value of $378,600.00. Following the sale, the chief operating officer directly owned 153,808 shares in the company, valued at approximately $11,646,341.76. This trade represents a 3.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 932,832 shares of company stock worth $71,324,324. 26.27% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Needham & Company LLC upped their price target on Tempus AI from $70.00 to $100.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. JPMorgan Chase & Co. decreased their target price on Tempus AI from $85.00 to $80.00 and set a “neutral” rating for the company in a research report on Monday, December 15th. Cowen lowered shares of Tempus AI from a “buy” rating to a “hold” rating in a research report on Tuesday, October 21st. Morgan Stanley boosted their price objective on shares of Tempus AI from $80.00 to $85.00 and gave the stock an “overweight” rating in a research note on Monday, December 1st. Finally, Piper Sandler decreased their price objective on shares of Tempus AI from $105.00 to $80.00 and set a “neutral” rating for the company in a report on Tuesday, November 11th. Seven investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Tempus AI presently has an average rating of “Hold” and an average price target of $84.00.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.